Hallén B, Guilbaud O, Strömberg S, Lindeke B
Department of Pharmacology, Statistics and Computer Services, KabiVitrum AB, Stockholm, Sweden.
Biopharm Drug Dispos. 1988 May-Jun;9(3):229-50. doi: 10.1002/bod.2510090302.
A bioequivalence study with terodiline (Mictrol) was performed in 8 healthy volunteers given a 25 mg oral dose of either of two solid dosage forms together with a water solution of the deuterated drug. The solid dosage forms were found to be bioequivalent. Moreover, their pharmacokinetic profiles were the same as for the water solution. The basic pharmacokinetic parameters (means +/- SE) of terodiline were calculated to: biological half-life in serum 60 +/- 4 h, maximum serum concentration 79 +/- 4 micrograms l-1 and the corresponding time 4 +/- 1 h, oral serum clearance 75 +/- 7 ml min-1, urinary excretion 15.3 +/- 1.5 per cent of dose, and renal serum clearance 10.9 +/- 2.2 ml min-1. The within-subject variability (serum-derived parameters) was about 8 per cent (CV per cent) and the between-subject variation 2-4 times higher. A single parameter estimate in subjects of a comparative population can be expected to show a 3-fold variation (95 per cent confidence). The deuterated drug could be used as a covariate to increase the power/precision in the statistical evaluation of the bioequivalence. In that way the 95 per cent confidence interval for the difference between the formulations, as well as the difference that could be detected with 80 per cent power, was reduced 2- to 5-fold. The covariate method was thus in this respect extremely efficient. In bioequivalence studies with drugs where a large number of subjects would be needed using conventional statistical analyses, this method also offers a possibility to considerably reduce the size of the panel, while retaining sufficient power and precision in the estimates.
对8名健康志愿者进行了替地林(Mictrol)的生物等效性研究,给他们口服25毫克两种固体剂型中的任何一种,并同时给予氘代药物的水溶液。发现这两种固体剂型具有生物等效性。此外,它们的药代动力学特征与水溶液相同。替地林的基本药代动力学参数(均值±标准误)计算如下:血清生物半衰期60±4小时,血清最大浓度79±4微克/升,相应时间4±1小时,口服血清清除率75±7毫升/分钟,尿排泄量为剂量的15.3±1.5%,肾血清清除率10.9±2.2毫升/分钟。受试者内变异性(源自血清的参数)约为8%(变异系数百分比),受试者间变异性则高2至4倍。可以预期,比较人群中受试者的单个参数估计值会有3倍的变异(95%置信度)。氘代药物可用作协变量,以提高生物等效性统计评估的效能/精度。通过这种方式,制剂间差异的95%置信区间以及能以80%效能检测到的差异缩小了2至5倍。因此,协变量法在这方面极其有效。在使用传统统计分析需要大量受试者的药物生物等效性研究中,这种方法还提供了大幅减少受试者数量的可能性,同时在估计中保持足够的效能和精度。